黑料官网

header-logo
GettyImages-609179959-hero
headshot

Sayed Mehdi H. Hamadani, MD

Professor

view physician profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Urdu, Hindi, Punjabi

Clinical Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Dr. Hamadani is a professor of medicine and chief of hematologic malignancies at the 黑料官网 (黑料官网) in Milwaukee, WI. He serves as the Associate Director of Clinical Research at the 黑料官网 Clinical Cancer Center and holds the Cancer Center Scholar Endowed Chair. Dr. Hamadani graduated with honors from King Edward Medical College (Pakistan), in 2001. He completed internal medicine residency from the University of Oklahoma followed by a fellowship in Hematology/Oncology at The Ohio State University. He is considered an international key opinion leader in the fields of hematopoietic cell transplantation, cellular therapy and lymphoid malignancies. He has authored over 450 peer-reviewed publications. As the Principal Protocol Officer for BMT CTN and Co-PI of 黑料官网 LAPS Grant he has extensive experience in clinical trial design and has been involved in the development and execution of several practice changing transplant clinical trials. He chairs the ASTCT Committee on Practice Guidelines and served as the Secretary of American Society for Transplant and Cellular Therapies (2024-26). His key areas of search include graft-versus-host disease (GvHD), developmental therapeutics for lymphoid malignancies and hematopoietic cell transplantation. His clinical expertise includes lymphomas, transplant, and CAR-T cell therapies. He considers mentoring junior faculty and trainees as his top-most priority.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Publications

  • (Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor Á, Townsend W, André M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C.) Blood Adv. 2025 Dec 09;9(23):6205-6217 PMID: 40811783 PMCID: PMC12745010 08/14/2025

  • (Ustun C, Zhang MJ, Peterson A, Baek A, Agha M, Alkhateeb H, Chhabra S, Coltoff A, de Lima M, Gandhi A, Ho V, Kassim A, Lin A, Gowda L, Borthakur G, DeAngelo DJ, McGuirk J, Mensah F, Nadiminti KV, Nishihori T, Pantin J, Trunk A, Uberti J, Marcucci G, Gotlib J, Akin C, Hamadani M, Pullarkat V, Valent P, Grunwald M, Juckett M, Oran B, Saber W, Burns LJ.) Br J Haematol. 2025 Dec;207(6):2486-2495 PMID: 40983528 PMCID: PMC12519450 SCOPUS ID: 2-s2.0-105016816308 09/23/2025

  • (Patel J, Gopal A, Cherniawsky H, Ram R, Kamble R, Hamadani M.) Haematologica. 2025 Nov 06 PMID: 41195517 11/06/2025

  • (Salles G, Fox CP, Hamadani M, Wang A, Sail K, Alshreef A, Moran M, Mutebi A, Blaedel J, Chirikov V, Thieblemont C.) Clin Lymphoma Myeloma Leuk. 2025 Nov;25(11):e986-e994.e4 PMID: 40903324 PMCID: PMC12425561 09/04/2025

  • (Narvel H, Ahmed G, Hamadani M.) Expert Rev Hematol. 2025 Nov;18(11):935-944 PMID: 40767562 08/06/2025

  • (Levis MJ, Hamadani M, Chen YB.) Blood Adv. 2025 Oct 29 PMID: 41160800 10/29/2025

  • (Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar OS, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, Jurdi NE, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Pérez WS, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M.) Transplant Cell Ther. 2025 Oct 07 PMID: 41027557 PMCID: PMC12606686 SCOPUS ID: 2-s2.0-105018107118 10/01/2025

  • (Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF.) Am J Hematol. 2025 Oct;100(10):1792-1802 PMID: 40785644 PMCID: PMC12608806 SCOPUS ID: 2-s2.0-105012974565 08/11/2025

  • (Thiruvengadam SK, Ahn KW, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera AF.) Am J Hematol. 2025 Oct;100(10):1803-1812 PMID: 40762207 PMCID: PMC12582634 SCOPUS ID: 2-s2.0-105012595303 08/05/2025

  • (Hamby M, Egleston B, Frosch Z, Steiner R, Noy A, Carvajal V, Chong E, Tolu S, Jean-Louis G, Amengual J, Patel R, Ahmed S, Sharp J, Voorhees T, Baiocchi R, Ramirez-Gamero A, Castillo J, Hamburger E, Dittus C, Nizamuddin I, Mehta-Shah N, Dar NNT, Sandoval-Sus J, Rojek A, Riedell P, Khan N, Danilov A, Solipuram V, Rubinstein P, Ariotti A, Suneja G, Vartanov A, Milrod C, Olszewski A, Smilnak G, Ayers E, Desai S, Rhodes J, Magarelli G, Feldman T, Pellon M, Aboulafia D, Bae W, Galvez C, Bhatlapenumarthi V, Hamadani M, Barta S.) Res Sq. 2025 Sep 30 PMID: 41255989 PMCID: PMC12622178 11/19/2025

  • (Shahzad M, Amin MK, Irfan S, Ahsan R, Qasim H, Javed MJ, McGuirk M, Chaudhary SG, Anwar I, Yacoub A, Singh AK, Hamadani M, Mcguirk JP, Mushtaq MU.) Clin Lymphoma Myeloma Leuk. 2025 Aug 17 PMID: 40930937 09/11/2025

  • (Shahzad M, Amin MK, Irfan S, Vyas A, Ahsan R, Chaudhary SG, Anwar I, McGuirk M, Iftikhar R, Abdelhakim H, Singh AK, Hamadani M, Mcguirk JP, Mushtaq MU.) Clin Lymphoma Myeloma Leuk. 2025 Aug 17 PMID: 40930936 09/11/2025

Publications of from the

© 2026 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.